In this regard, evidence from the phase II MiST4 trial (NCT03654833), which evaluated dual inhibition of PD-L1 (atezolizumab) and VEGF (bevacizumab) in 26 patients with relapsed mesothelioma, unveiled a significant association between the specific composition of gut microbial communities and clinical outcomes [32]. The gene discussed is VEGFA; the disease is mesothelioma.